Local Immunotherapy Halts Precancerous Oral Lesions in Clinical Trial

A phase I clinical trial has shown that injecting immunotherapy directly into precancerous oral lesions can lead to tumor shrinkage without causing dose-limiting toxicities, according to findings presented by researchers and reported in multiple health and science outlets.

The treatment involved the use of nivolumab, an immune checkpoint inhibitor, administered via intralesional injection in patients with oral precancers. Researchers observed that this localized approach reduced lesion size and may lower the risk of progression to cancer, potentially avoiding the need for surgical intervention in some cases.

Prior research had indicated that nivolumab could be effective in treating certain precancerous conditions, but this trial marks one of the first instances where direct injection into oral lesions was tested in a clinical setting. The absence of dose-limiting toxicities suggests the method is well-tolerated at the tested levels.

Experts note that oral precancers, such as leukoplakia or erythroplakia, often require monitoring or surgical removal due to their potential to develop into oral squamous cell carcinoma. A non-surgical option that can shrink lesions while maintaining a favorable safety profile could represent a meaningful advancement in preventive care for high-risk patients.

The findings were shared in the context of ongoing research into immunotherapy’s role beyond advanced cancer treatment, extending into early interception strategies. While the trial was small and focused on safety and preliminary efficacy, researchers suggest that larger studies will be needed to confirm long-term outcomes and optimal dosing regimens.

No specific survival rates or comparative statistics against standard treatments were provided in the available reports. The trial did not assess whether the treatment eliminates the risk of cancer development entirely, only that it reduced visible lesion size during the observation period.

As with all early-phase trials, the results are promising but not conclusive. Researchers emphasized that immunotherapy is not yet a standard treatment for oral precancers and that patients should continue to follow established screening and monitoring guidelines under the care of a qualified healthcare provider.

Further investigation will focus on determining whether intralesional immunotherapy can durably suppress lesion recurrence, prevent progression to invasive cancer, and reduce reliance on surgery or radiation in broader patient populations.